



FINANCIAL CONTRIBUTION AGREEMENT

This Financial Contribution Agreement (“Agreement”) is made between:

SANOFI A/S, a company duly organized under the laws of Denmark under the business identity number 19064301 and having its registered office located at Vibenshuset, Lyngbyvej 2, 2100 København Ø - Denmark (hereinafter referred to as “Sanofi”)

and

Eksemforening with chairperson Anne Vastrup, Hvidovrevej 108, 1. tv., 2650 Hvidovre, Denmark (“Recipient”)

WHEREAS

- A. Sanofi is a diversified human healthcare Sanofi engaged in the research, design, development, production, marketing, distribution and sale of medicinal products and services;
- B. Recipient is Eksemforening with chairperson Anne Vastrup
- C. Recipient appointed Decisions, a company with registered address: Frederiksborggade 1A, 1.th.1360 København K, Danmark (“Organizer”), to take care of the execution of the disease awareness initiative ‘. Sanofi will pay Decisions directly.

Recipient will use the funds to increasing awareness of chronic skin diseases and in particular eczema with the event AD-dagen 2025: Rundbordsmøde på Christiansborg om behandlingsgaranti.

- D. Recipient has requested Sanofi for support in the project by means of a financial contribution and Sanofi has agreed to do so. The transferal of value from Sanofi to the individual associations is 100 000 DKK in total and the project will be executed by Decisions the agency of choice for Eksemforening for this project.

NOW THEREFORE, the parties hereto agree as follows:

1. Obligations of Sanofi

- 1.1 Subject to the terms and conditions of this Agreement, Sanofi shall support the Project by means of a financial contribution in the amount of 100 000 DKK. This contribution will be paid to Decisions – the agency of choice for this project by Eksemforening. The disease awareness initiative is co-sponsored by other pharma companies. The initiative is owned by the Recipient and produced and project managed in cooperation with the agency Decisions.
- 1.2 The Financial Contribution will be paid within 30 (thirty) calendar days following the receipt of an invoice, which is to be sent after the effective date of this Agreement.
- 1.3 Invoices must contain the following information:



- Sanofi name and address
- Sanofi's VAT registration number:
- Sanofi's Purchase Order number *PO number to be provided later*
- Invoice date
- Unique invoice number
- Recipient's bank account details
 - Bank Account Number
 - Name and Address of Bank
 - IBAN code
 - BIC / SWIFT code
- Any VAT references as required (Recipient is responsible for the correct VAT treatment)

1.4 Invoices should be sent by e-mail to invoicesDK@sanofi.com (one PDF or TIFF file per message) containing one request for payment and any attachments."

2 Obligations of Recipient

2.1 The Financial Contribution is given solely for the organization of the Project and shall not be used by Recipient for any other purpose without Sanofi's prior written consent.

A more detailed description of the Project, including a budget, is attached hereto as Exhibit A and B.

2.2 Recipient acknowledges the fact that Sanofi is a pharmaceutical company and can only financially support the Project if the Project as such meets the requirements of the EFPIA Member Association's Code of Practice in the country. In view thereof, Recipient represents and warrants that in the organization of the Project it shall abide by aforesaid requirements and, more generally, refrain from any acts and activities that (may) affect the legitimacy of Sanofi's Financial Contribution.

2.3 At Sanofi's request, Recipient shall fully disclose to Sanofi how the Financial Contribution has actually been spent.

2.4 Recipient shall clearly and legibly state in its communications related to the Project that the Project was 'made possible in part by Sanofi.

2.4 In return for the Financial Contribution provided by Sanofi, Recipient shall execute the disease awareness initiative as described in the application.

3. Transparency

3.1 Parties agree that the Financial Contribution made by Sanofi under this Agreement is subject to the provisions on disclosure of transfers of value between pharmaceutical companies, patient organizations and healthcare organizations as set forth in the EFPIA Member Association's Code of Practice in Recipient's country of registration (the "National Code of Practice").

3.2 Parties agree that Sanofi's local affiliate in Recipient's country of registration, Sanofi A/S Denmark, will take care of disclosure of the Financial Contribution in accordance with the



relevant provisions of the National Code of Practice. To that end, Recipient hereby authorizes Sanofi to share with its local affiliate all information and details pertaining to Recipient and this Agreement as Sanofi's local affiliate may require for disclosure purposes in line with the National Code of Practice.

4. Data Protection

The Parties will process all personal data obtained during the term of this Agreement in accordance with applicable data protection laws and regulations including but not limited to the General Data Protection Regulation (EU) 2016/679 and its amendments.

5. Compliance Undertakings

5.1 Parties represent and warrant that

- in the execution of this Agreement they will comply with all applicable laws and (self-) regulations, including - but not limited to - the National Code of Practice (as defined in Article 3.2 above), data protection and anti-bribery legislation such as the UK Bribery Act 2010; and
- they, and where relevant, their directors, officers, employees, agents or subcontractors shall not, directly or indirectly pay or promise to pay, or authorize the payment of any money, or give, promise to give or authorize the giving of anything of value to any government official, healthcare professional or person affiliated with a healthcare organization to obtain or retain business or secure improper advantage to Sanofi.

5.2 Parties acknowledge that the Financial Contribution of Sanofi does not take effect and is not intended to take effect as an incentive or reward for Recipient's past, present or future willingness to prescribe, administer, recommend (including formulary recommendations), purchase, pay for, reimburse, authorize, approve or supply any product or service sold or provided by Sanofi or as an incentive to grant an interview for any sales or marketing purposes.

6 Miscellaneous

6.1 During the term of this Agreement and thereafter, each party shall keep in trust and confidence and not disclose to others all information it receives from the other party, provided however that these non-disclosure obligations do not apply to such (portion of) information that (i) at the time of disclosure is available in the public domain, (ii) after disclosure becomes available in the public domain through no fault of the receiving party, (iii) is required to be disclosed under applicable laws or (self-) regulations, including the National Code of Practice (as defined in Article 3.2 above), or (iv) is already in the possession of the other party.

6.2 This Agreement shall not be assigned or otherwise transferred by either party without the prior written consent of the other party; provided however that Sanofi may assign this Agreement to any of its affiliates or to a successor to its business (whether by merger, a sale of all or substantially all of its assets relating to this Agreement, a sale of its capital stock, or otherwise).

6.3 Either party may terminate this Agreement with immediate effect by written notice to the other party, if the other party commits a breach of this Agreement and the breach is not



remedied within thirty (30) days after service of written notice requiring the same. If a party terminates this Agreement in accordance with this Article 6.3, the other party shall not be entitled to any compensation, indemnity or damages or other payment in respect of such termination. Article 3, Article 5.0, Articles 7.2 and 7.3 and all other provisions of this Agreement, including any Exhibit, that expressly or by their nature survive termination of this Agreement, shall continue in full force and effect subsequent to and notwithstanding such termination.

6.4 Sanofi shall have the right during the term of this Agreement and three (3) years thereafter to audit whether Recipient's use of the Financial Contribution is in accordance with this Agreement.

7. Effective Date, Governing Law and Dispute Resolution

7.1 This Agreement becomes effective when signed by an authorized representative of each party. A signed Agreement may be delivered by any reasonable means, including facsimile or other electronic transmission

7.2 The Agreement shall be governed by the laws of Denmark without reference to its conflict of laws provisions. The Parties shall try to solve by prior good faith negotiations any difficulties that may arise between them in the performance or construction of the Agreement. Should the Parties fail to reach an agreement, the Parties agree to submit the dispute to the exclusive jurisdiction of the competent court of Copenhagen, notwithstanding plurality of defendants, summary proceedings or impleader.

IN WITNESS WHEREOF, the Parties have duly executed this Agreement.

SANOFI

Signature: 
 Birgitte Fyhn (Jun 18, 2025 07:47 GMT+2)

Date: 06/18/2025

Name: Birgitte Fyhn

Title: Head of Market Access & External Affairs Denmark

Recipient

Signature*: 
 Anne Skov Vastrup (Jun 14, 2025 19:35 GMT+2)

Date: 06/14/2025

Name: Anne Vastrup

Title: Chair Person, Eksemforeningen



Exhibit A

Anmodning om støtte til rundbordsmøde på Christiansborg om behandlingsgaranti AD-dagen 2025: Rundbordsmøde på Christiansborg om behandlingsgaranti

I forbindelse med Sundhedsreformen er der indført behandlingsgaranti hos praktiserende speciallæger såvel som en forsøgsordning, hvor biologiske behandlinger flyttes fra hospitaler til praktiserende speciallæger.

Udfordringen er dog, at behandlingsgarantien skal opnås ved at skabe større kapacitet hos eksisterende speciallæger samt, at der først fremsættes lovforslag om behandlingsgarantien i 2026.

I Eksemforeningen glæder vi os over tiltagene, men med en ventetid på 22 uger for at komme til hudlæge (landsgennemsnit) ser vi også et stort behov for at diskutere tiltag, der kan øge kapaciteten hos de praktiserende hudlæger.

Vi ønsker derfor at afholde et rundbordsmøde på Christiansborg, hvor politikere, embedsmænd, sundhedsfaglige og patienter kan diskutere processen vedr. behandlingsgarantien. Mødet skal runde ud i en publikation med forslag til, hvordan vi kan skabe større kapacitet hos speciallægerne – og publikationen fremsendes til Folketingets Sundhedsudvalg samt relevante embedsmænd i Sundhedsministeriet.

Økonomisk anmodning

Vi vil gerne samarbejde med Decisions om rundbordsmøde mv. samt lade dem stå for fakturering og projektstyring. Vi søger støtte hos både AbbVie, Ammirall, LEO Pharma, Pfizer og Sanofi, og i forhåbning om at to til tre selskaber har lyst og mulighed for at bakke op, anmoder vi Sanofi om 100.000 kr. til projektet, der samlet lyder på 168.680 kr. før moms, jf. vedhæftede oplæg.

På forhånd mange tak for opbakningen til foreningens arbejde.

Mange hilsner fra

Anne Skov Vastrup, forperson i Eksemforeningen

BILAG

- Oplæg til ADdagen 2025

Exhibit B Budget

Budget

Alle priser er eksklusive moms. Eksempforeningen vil gerne finansiere AD-dagen med sponsorater til foreningen, hvorfor der skal lægges moms til vores finansieringsbehov. Vi søger om fem sponsorater af 42.170 kr. inklusive moms eller 33.736 eksklusive moms.

Opgaven:	Timer	Udgift timer	Ekstern udgift	Pris i alt DKK
Udarbejdelse af købte og organiske opslag på SofMe	6	9.120	30.000	39.120
Process og udarbejdelse af to debatindlæg	13	23.560	0	23.560
Rundbordsrunde inklusiv invitation og facilitering	26	43.320	0	43.320
Udarbejdelse af publikation	14	22.800	0	22.800
Mediekøb på sociale medier	0	0	30.000	30.000
Projektledebe	6	9.880	0	9.880
Pris i alt eksklusiv moms	65	108.680	60.000	168.680
Pris inklusive moms				210.850